Patient preference in a crossover clinical trial of patients with osteoarthritis of the knee or hip: Face validity of self-report questionnaire ratings

Journal of Rheumatology

Volumn 32, Issue 3, 2005, Pages 533-539

  Pincus, Theodore ^a   Wang, Xiaofei ^b   Chung, Cecilia ^a   Sokka, Tuulikki ^a   Koch, Gary G ^c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

^c IL   (United States)

Author keywords

Acetaminophen; Crossover clinical trial; Diclofenac Misoprostol; Osteoarthritis; Patient preference

Indexed keywords

ARTHROTEC; PARACETAMOL;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DRUG EFFICACY; HIP OSTEOARTHRITIS; HUMAN; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; PHYSICIAN; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SELF REPORT; VISUAL ANALOG SCALE;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CROSS-OVER STUDIES; DICLOFENAC; DOUBLE-BLIND METHOD; HUMANS; MISOPROSTOL; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PATIENT SATISFACTION; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS;

EID: 15044351323     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Pocock SJ. Clinical trials: a practical approach. New York: John Wiley and Sons; 1983.
2. Friedman LM, Furberg CD, DeMets DL. Fundamentals of clinical trials. New York: Springer-Verlag; 1998.
3. Koch GG, Amara IA, Brown BW Jr, Colton T, Gillings DB. A two-period crossover design for the comparison of two active treatments and placebo. Stat Med 1989;8:487-504.
4. Senn S. Cross-over trials in clinical research. New York: John Wiley and Sons: 1994.
5. Jones B, Kenward MG. Design and analysis of crossover trials. 2nd ed. London: Chapman and Hall; 2003.
6. Pincus T, Koch GG, Sokka T, et al. A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 2001;44:1587-98.
7. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: A health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40.
8. Bellamy N. Pain assessment in osteoarthritis: experience with the WOMAC osteoarthritis index. Semin Arthritis Rheum 1989;18 Suppl 2:14-7.
9. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
10. Pincus T, Swearingen C, Wolfe F. Toward a multidimensional Health Assessment Questionnaire (MDHAQ): Assessment of advanced activities of daily living and psychological status in the patient friendly health assessment questionnaire format. Arthritis Rheum 1999;42:2220-30.
11. Wolfe F. The importance of gastrointestinal (GI) symptom severity in rheumatoid and osteoarthritis: symptom rates and risk for GI hospitalization. J Rheumatol 2000;27:1661-7.
12. Wolfe F, Hawley DJ. The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients. J Rheumatol 2000;27:1668-73.
13. Gall ER, Caperton EM, McComb JE, et al. Clinical comparison of ibuprofen, fenoprofen calcium, naproxen and tolmetin sodium in rheumatoid arthritis. J Rheumatol 1982;9:402-7.
14. Caldwell JR, Crain D, Hoffmeister RT, et al. Four-way, multicenter, crossover trial of ibuprofen, fenoprofen calcium, naproxen, and tolmetin sodium in osteoarthritis: comparative clinical profiles. South Med J 1983;76:706-11.
15. Pincus T, Callahan LF. Clinical use of multiple nonsteroidal antiinflammatory drug preparations within individual rheumatology private practices. J Rheumatol 1989;16:1253-8.
16. Pincus T. Marcum SB, Callahan LF, et al. Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices: I. Nonsteroidal anti-inflammatory drugs. J Rheumatol 1992;19:1874-84.
17. Stein CM. Wood AJJ, Pincus T. Implementation of multiple outpatient formularies: Undesirable effects. Clin Pharmacol Ther 1997;61:1-7.
18. Engel GL. The need for a new medical model: a challenge for biomedicine. Science 1977;196:129-36.
19. Callahan LF, Pincus T. Education, self-care, and outcomes of rheumatic diseases: Further challenges to the "biomedical model" paradigm. Arthritis Care Res 1997;10:283-8.
20. Pincus T. Challenges to the biomedical model: Are actions of patients almost always as important as actions of health professionals in long-term outcomes of chronic diseases? [editorial]. Adv Mind Body Med 2000;16:287-94.
21. Fries JF, Ramey DR. "Arthritis specific" global health analog scales assess "generic" health related quality-of-life in patients with rheumatoid arthritis. J Rheumatol 1997;24:1697-702.
22. Wolfe F, Pincus T, Fries JF. Usefulness of the HAQ in the clinic [letter]. Ann Rheum Dis 2001;60:811.
23. Pincus T. Documenting quality management in rheumatic disease: Are patient questionnaires the best (and only) method? Arthritis Care Res 1996;9:339-48.
24. Pincus T, Wolfe F. An infrastructure of patient questionnaires at each rheumatology visit: Improving efficiency and documenting care. J Rheumatol 2000;27:2727-30.
25. Fries JF. New instruments for assessing disability: not quite ready for prime time. Arthritis Rheum 2004;50:3064-67.
26. Kvien TK, Glennås A, Knudsrod OG, Smedstad LM. The validity of self-reported diagnosis of rheumatoid arthritis: Results from a